SCHEMBL2072826

SCHEMBL2072826

COc1cccc2[nH]cc(C=C3C(=O)OC(C)(C)OC3=O)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 3/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
ALDH1A1 P00352 4/20 0.44
HTR2A P28223 2/20 0.42
HTR6 P50406 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
HSD17B10 Q99714 2/20 0.40
MAPK1 P28482 1/20 0.40
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
MMP9 P14780 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13451359 0.82 HTR2A (0.37) SIRT1KMT2AKDM4ENPC1RAB9A
SCHEMBL29955729 0.76 CYP2A6 (0.58) MAPTKDM4EALDH1A1HTR2AHTR6
SCHEMBL1337138 0.76 CYP2A6 (0.58) MAPTKDM4EALDH1A1HTR2AHTR6
SCHEMBL2498778 0.74 SIRT1 (0.57) SIRT1KMT2AMEN1MAPTNPC1
SCHEMBL28167758 0.69 HTR2A (0.60) KMT2AMEN1HTR2AHTR6HTR2C
SCHEMBL13451360 0.69 HTR2A (0.38) KMT2AMEN1KDM4ENPC1RAB9A
SCHEMBL23493550 0.68 PRMT1 (0.58) MAPTALDH1A1HTR2AHTR6HTR2C
SCHEMBL2537322 0.68 PRMT1 (0.58) MAPTALDH1A1HTR2AHTR6HTR2C
SCHEMBL30418664 0.68 PRMT1 (0.58) MAPTALDH1A1HTR2AHTR6HTR2C
SCHEMBL2537326 0.68 PRMT1 (0.58) MAPTALDH1A1HTR2AHTR6HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863305-B2 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC (US) 2011-01-04 US disclosed
US-7863305-B2 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC (US) 2011-01-04 US disclosed
US-7863305-B2 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC (US) 2011-01-04 US disclosed
EP-1756054-B1 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR HOFFMANN LA ROCHE (CH) 2010-03-31 EP disclosed
EP-1756054-A1 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR F.HOFFMANN-LA ROCHE AG (CH) 2007-02-28 EP disclosed
US-20060025467-A1 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC 2006-02-02 US disclosed
WO-2005118539-A1 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR F.HOFFMANN-LA ROCHE AG (CH) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025467-A1 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors TPH1, HTR1A, HTR3A SIRT1 1473/4885KMT2A 920/4885MEN1 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.